Stock·NASDAQ·Consumer Cyclical
Hasbro Inc (HAS)
- Market cap
- $16.63B
- P/E
- 17.72
- Dividend yield
- 2.35%
- Street target
- $120.00median of 14 analysts
- 52-week range
- $74.78 $124.00
HAS stock forecast today
Where HAS stands today, and what CleaRank Financial AI makes of it.
HAS at a glance
Hasbro Inc (HAS): Buy, 76/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($98.78 and $93.25).
- Earnings HAS beat estimates in 5 of its last 5 quarters, yet fell in the first session after 2 of those beats.
- Insiders Insiders sold $53.3M and made no open-market purchases over the last 18 months.
- Valuation P/E of 17.7 against 20.8 for the Consumer Cyclical sector: broadly in line with peers (-15%).
Figures as of November 6, 2026.
CleaRank Financial AI
CleaRank rates Hasbro Inc (HAS) Buy with a model score of 76/100.
Trend adds the most to that score: the price is 27.51% above its 200-day average and 20.38% above its 50-day average, and the 50-day average is 5.93% above the 200-day. Valuation pulls it down the most, with the P/S of 3.21 68.9% above the sector median. The 50-day average is $98.78 and the 200-day is $93.25. Across the past year, the price climbed 55.21%.
Only on CleaRank
Figures we compute ourselves from HAS's own price, earnings and insider-filing history. Tap one to see it in context.
HAS stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $118.91 is 20.4% above the 50-day simple moving average of $98.78.Price above its 200-day average ›
The price is 27.5% above the 200-day simple moving average of $93.25.50-day average above the 200-day ›
The 50-day average ($98.78) is 5.9% above the 200-day average ($93.25), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 90% of its 52-week range, between $74.78 and $124.00.
HAS share price
Pick a period: each tab shows how far HAS has moved over it, to the last close.
Today's trading
Where HAS sits inside today's range and its 52-week range.
HAS fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/5P/E below the sector median ›
The trailing P/E of 17.72 is 14.8% below the Consumer Cyclical median of 20.8.P/S above the sector median ›
The price-to-sales ratio of 3.21 is 68.9% above the sector median of 1.9.Profitable over the last 12 months ›
Net income over the last 12 months was $955.4M on revenue of $5.2B, a net margin of 18.4%.Beat estimates in most recent reports ›
HAS beat the EPS estimate in 5 of its last 5 reports.Pays a dividend ›
The trailing dividend yield is 2.35%, or $2.80 a share a year.
Key statistics
The headline figures for HAS.
As of November 6, 2026, HAS trades at $118.91, with a market value of $16.63B, a P/E ratio of 17.72 and a dividend yield of 2.35%.
What the numbers say
CleaRank Financial AI's reading of HAS's valuation, growth and risks.
HAS trades at 17.72 times earnings, compared with a Consumer Cyclical median of 20.8. That leaves the P/E 14.8% below the median, and the P/E is broadly in line with peers. On sales, the stock is priced at 3.21 times, which is 68.9% above the sector median of 1.9. Trailing earnings stand at $6.71 a share.
Its net margin of 18.44% and operating margin of 32.43% show how much of each sale reaches profit, and its return on equity of 139.78% sits above the sector median of 12.4%. On the balance sheet, debt-to-equity stands at 4.10, and the trailing dividend yield of 2.35% works out to $2.80 a share per year.
The October 20, 2026 report delivered EPS of $2.90, well ahead of the $1.85 estimate, a beat of 56.76%. In the first session after the report, the share price climbed 4.09%.
HAS has beaten the EPS estimate in all 5 of its recent reports, but beats have not guaranteed gains: the stock fell in the first session after 2 of them. Looking ahead, analysts expect EPS of $7.12 this fiscal year (growth of 28.5%) and $6.98 the year after (a decline of 2.0%).
The 30-day standard deviation of HAS's daily returns is 2.45%, and its beta against the S&P 500 is 0.36. Insiders sold $53.3M over the last 18 months and bought none on the open market, though sales of this kind are often planned in advance and say less than purchases would.
HAS against the Consumer Cyclical sector
How HAS compares with the median Consumer Cyclical stock CleaRank tracks.
Price to earnings vs sector: Valuation is broadly in line with sector peers (-15% against the sector median P/E).
Return vs SPY: Since May 28, 2025, HAS has gained 79.4% against a gain of 25.1% for SPY.
Performance against SPY
HAS and the S&P 500 (SPY) over the same days.
Revenue and earnings
How much HAS sells, and how much of it becomes profit.
The quarterly bars end with Q2 '26 (the quarter to June 30, 2026); HAS reported again on October 20, 2026, and that quarter is not in our statement data yet. The 12-month figures come from the statistics feed and may include it.
Revenue growth: Revenue grew 13.7% in FY2025 to $4.7B, from $4.1B a year earlier.
Profit margin: The net margin was -6.8% in FY2025, down from 9.5% the year before.
Loss-making: HAS lost $318M in FY2025.
Earnings reality check
Did HAS beat what analysts expected, and how did the stock react?
Earnings record: HAS beat the analyst estimate in 5 of the last 5 quarters.
Market reaction: The stock fell in the first session after 2 of those 5 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Oct 20, 2026 | $1.85 | $2.90 | +56.76% | +4.09% | +8.04% |
| May 13, 2026 | $1.13 | $1.47 | +30.09% | +1.74% | -5.75% |
| Oct 23, 2025 | $1.63 | $1.68 | +3.07% | -1.59% | -1.78% |
| Jul 23, 2025 | $0.77 | $1.30 | +68.83% | -2.33% | -1.09% |
| Apr 24, 2025 | $0.67 | $1.04 | +55.22% | +1.03% | +0.56% |
As of November 6, 2026, HAS has beaten the analyst EPS estimate in 5 of its last 5 reported quarters and fell in the first trading session after 2 of those beats; its latest report, on October 20, 2026, came in 56.76% above the estimate and the stock moved +4.09% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
HAS AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI overbought or oversold ›
The 14-day RSI is 74.7, in overbought territory.RSI above 50 ›
An RSI of 74.7 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of HAS
The score, the reasoning behind it, and what could move the price next.
Both moving averages sit under the price, which is the shape of an uptrend for HAS: the price of $118.91 is 20.38% above the 50-day average ($98.78) and 27.51% above the 200-day average ($93.25). The price sits near the top of its 52-week range, 4.10% below the high of $124.00 and 59.01% above the low of $74.78. The 50-day average sits 5.93% above the 200-day, which confirms the move rather than contradicting it.
HAS shows a 14-day RSI of 74.7, which places it in overbought territory, while the MACD line sits in positive territory. Over the past month the price gained 27.15%, over three months 27.15%, and over the past year 55.21%.
Earnings beat ›
The October 20, 2026 report beat the EPS estimate by 56.76%, and the share price rose 4.09% in the first session after it.
Source: Earnings report, October 20, 2026Rating reaffirmed ›
UBS kept its Buy rating on October 28, 2026.
Source: Analyst action, UBS, October 28, 2026
- Two levels matter most right now. Above the price, the 52-week high sits at $124.00. Below it, the 20-day EMA at $112.30 is the first line a fall would meet.
- A 14-day RSI of 74.7 lands in the overbought zone, and the MACD line is positive. Readings above 70 or below 30 would mark stretched momentum.
- HAS beat estimates in 5 of the last 5 reports. After the October 20, 2026 report, the share price rose 4.09% in the first session.
HAS's uptrend depends on the price holding above its 50-day average of $98.78 and its 200-day average of $93.25. A close below the 50-day average would be the first sign of weakness. If the price pulls back, the first level it would reach is the 20-day EMA at $112.30.
The 52-week high at $124.00 is the next level overhead. The RSI is stretched above the overbought line, so a cooling of momentum would not be unusual even inside the uptrend.
Technical indicators
Momentum and trend for HAS, from its daily closes.
As of November 6, 2026, with HAS at $118.91, its 14-day RSI is 74.7 (overbought territory), its 50-day simple moving average is $98.78 and its 200-day is $93.25.
Calculated by CleaRank on daily closes as of November 6, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What HAS moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of November 6, 2026, HAS's 1-year correlation of daily returns is +0.45 with S&P 500 (SPY), +0.34 with Nasdaq 100 (QQQ), +0.05 with Bitcoin (BTC) and +0.04 with gold (XAU).
HAS price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
12 of 14 analysts rate it a buy or strong buy, 2 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $120.00 is 0.9% above the price.Buy share not up from three months ago ›
12 of 14 rate it a buy now, against 13 of 15 three months ago.
HAS Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 28, 2026 | UBS | Maintains | Buy |
| Oct 21, 2026 | Citigroup | Maintains | Buy |
| Oct 21, 2026 | Wells Fargo | Maintains | Equal-Weight |
| Oct 21, 2026 | BNP Paribas | Reiterates | Outperform |
| Oct 13, 2026 | Citigroup | Maintains | Buy |
| Aug 20, 2026 | Wells Fargo | Maintains | Equal-Weight |
As of November 6, 2026, 14 Wall Street analysts cover HAS: 12 rate it a buy or strong buy, 2 a hold and 0 a sell or strong sell. Their 12-month price targets range from $100.00 to $137.00. The median HAS price target is $120.00, 0.9% above the price of $118.91.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
HAS risk and volatility
How much it moves day to day, and how it stacks up against similar assets.
Risk profile
How much HAS tends to move, against the market and on its own.
HAS price history and drawdowns
HAS's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/4Typical daily move of 2% or more ›
A typical daily move is 2.45% (the standard deviation of the last 30 daily returns).Recovered from its worst fall ›
The worst fall was 63.1%, from July 2019 to March 2020, regained by February 2026.Most 1-year holds ended higher ›
58% of 1-year holding periods in the last 10 years ended with a gain.Trailed the S&P 500 since December 2016 ›
$10,000 invested in December 2016 is now worth $19,636, against $39,188 in the S&P 500 (SPY).
HAS Drawdowns & Recovery
As of November 6, 2026, HAS's worst peak-to-trough fall over the last 10 years with dividends reinvested was -63.1% (July 2019 to March 2020); it regained that peak by February 2026, 71 months after the low, and 58% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into HAS in December 2016 is worth now, against the same amount in the S&P 500.
Against the market: HAS trailed the S&P 500 over this period: $19,636 against $39,188.
A $10,000 investment in HAS in December 2016 would be worth about $19,636 today with dividends reinvested, compared with about $39,188 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to HAS, and which have not.
Strongest month, April: an average of +7.32%, up in 8 of 10 years.
Weakest month, March: an average of -4.66%, up in 4 of 10 years.
This month, November: has averaged +1.18%, up in 6 of 9 years. Past seasonality does not repeat on schedule.
Across 10 calendar years of history, HAS's strongest calendar month has been April (average +7.32%, up in 8 of 10 years) and its weakest March (average -4.66%, up in 4 of 10 years).
Average return for each calendar month across 10 calendar years of history, from weekly closing prices with dividends included.
HAS stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in HAS, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in HAS today could grow to about $12,177 by 2030 in the base case, with a 90th-percentile outcome near $29,283 and a 10th-percentile outcome around $5,063. The simulation models price only; at today's 2.35% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
HAS Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $145 for HAS by 2030 in the base case, from $119 today (1.2x over 4 years). The 10th-percentile path ends near $60.21. These are outcomes of a Monte Carlo simulation run on HAS's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $80.55 | $125 | $194 | |
| 2028 | $70.55 | $131 | $244 | |
| 2029 | $64.47 | $138 | $295 | |
| 2030 | $60.21 | $145 | $348 |
Method: a lognormal simulation of HAS's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
HAS insider trading
What the people running the company have bought and sold.
HAS insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: No insider bought HAS shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of November 6, 2026, HAS insiders reported 20 open-market sales worth $53.3M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 31, 2026 | Holly Barbacovi
Officer
|
Sell | 5.1K | $476.4K |
| Aug 26, 2026 | Elizabeth Hamren
Director
|
Grant | 1.5K | - |
| Aug 19, 2026 | John Hight
Officer
|
Sell | 11.6K | $1.1M |
| Aug 17, 2026 | John Hight
Officer
|
Sell | 11.2K | $1.1M |
| Aug 14, 2026 | Holly Barbacovi
Officer
|
Grant | 1.2K | $115.3K |
| Aug 14, 2026 | John Hight
Officer
|
Grant | 1.4K | $134.5K |
| Aug 7, 2026 | Elizabeth Hamren
Director
|
Sell | 3.0K | $272.8K |
| Jul 31, 2026 | Gina M Goetter
Chief Financial Officer
|
Sell | 8.3K | $776.6K |
| Jul 30, 2026 | John Hight
Officer
|
Sell | 3.2K | $298.6K |
| Jul 28, 2026 | Timothy J Kilpin
Officer
|
Sell | 20.0K | $1.9M |
| Jul 28, 2026 | Gina M Goetter
Chief Financial Officer
|
Sell | 11.0K | $1.0M |
| Jul 28, 2026 | Timothy J Kilpin
Officer
|
Option | 20.0K | $1.2M |
| Jun 11, 2026 | Douglas S Bowser
Director
|
Grant | 2.2K | - |
| Jun 11, 2026 | Hope F Cochran
Director
|
Grant | 2.2K | - |
| Jun 11, 2026 | Lisa Gersh
Director
|
Grant | 2.2K | - |
| Jun 11, 2026 | Frank D Gibeau
Director
|
Grant | 2.2K | - |
| Jun 11, 2026 | Elizabeth Hamren
Director
|
Grant | 2.2K | - |
| Jun 11, 2026 | Darin S Harris
Director
|
Grant | 2.2K | - |
| Jun 11, 2026 | Owen Mahoney
Director
|
Grant | 2.2K | - |
| Jun 11, 2026 | Laurel J Richie
Director
|
Grant | 2.2K | - |
| Jun 11, 2026 | Richard S. Stoddart
Chairman of the Board
|
Grant | 2.2K | - |
| Jun 11, 2026 | Carla Vernon
Director
|
Grant | 2.2K | - |
| Mar 16, 2026 | Holly Barbacovi
Officer
|
Grant | 6.9K | - |
| Mar 16, 2026 | Jason M Bunge
Officer
|
Grant | 4.5K | - |
| Mar 16, 2026 | Christian P Cocks
Chief Executive Officer
|
Grant | 56.1K | - |
| Mar 16, 2026 | Gina M Goetter
Chief Financial Officer
|
Grant | 21.4K | - |
| Mar 16, 2026 | John Hight
Officer
|
Grant | 10.7K | - |
| Mar 16, 2026 | Tarrant Livingston Sibley III
Officer
|
Grant | 8.4K | - |
| Feb 26, 2026 | Christian P Cocks
Chief Executive Officer
|
Sell | 196.4K | $19.7M |
| Feb 26, 2026 | Christian P Cocks
Chief Executive Officer
|
Option | 196.4K | $11.0M |
| Feb 20, 2026 | Holly Barbacovi
Officer
|
Sell | 4.3K | $437.9K |
| Feb 20, 2026 | Christian P Cocks
Chief Executive Officer
|
Grant | 97.8K | - |
| Feb 20, 2026 | Timothy J Kilpin
Officer
|
Grant | 14.2K | - |
| Feb 20, 2026 | Tarrant Livingston Sibley III
Officer
|
Grant | 20.5K | - |
| Feb 13, 2026 | Timothy J Kilpin
Officer
|
Sell | 7.8K | $800.6K |
| Feb 12, 2026 | Christian P Cocks
Chief Executive Officer
|
Sell | 181.6K | $18.9M |
| Feb 12, 2026 | Tarrant Livingston Sibley III
Officer
|
Sell | 15.1K | $1.6M |
| Feb 12, 2026 | Gina M Goetter
Chief Financial Officer
|
Sell | 12.4K | $1.3M |
| Feb 12, 2026 | Jason M Bunge
Officer
|
Sell | 2.4K | $252.3K |
| Feb 12, 2026 | Christian P Cocks
Chief Executive Officer
|
Option | 181.6K | $15.6M |
| Feb 12, 2026 | Tarrant Livingston Sibley III
Officer
|
Option | 15.1K | $1.3M |
| Jan 16, 2026 | Douglas S Bowser
Director
|
Grant | 750 | - |
| Jan 16, 2026 | Carla Vernon
Director
|
Grant | 750 | - |
| Nov 10, 2025 | Hope F Cochran
Director
|
Sell | 4.0K | $309.0K |
| Aug 28, 2025 | Roberta Kelly Thomson
Officer
|
Sell | 2.5K | $202.8K |
| Aug 27, 2025 | Timothy J Kilpin
Officer
|
Sell | 8.6K | $696.9K |
| Aug 21, 2025 | Christian P Cocks
Chief Executive Officer
|
Sell | 27.8K | $2.2M |
| Aug 14, 2025 | Roberta Kelly Thomson
Officer
|
Sell | 1.0K | $80.0K |
| May 21, 2025 | Hope F Cochran
Director
|
Grant | 2.6K | - |
| May 21, 2025 | Lisa Gersh
Director
|
Grant | 2.6K | - |
| May 21, 2025 | Frank D Gibeau
Director
|
Grant | 2.6K | - |
| May 21, 2025 | Elizabeth Hamren
Director
|
Grant | 2.6K | - |
| May 21, 2025 | Darin S Harris
Director
|
Grant | 2.6K | - |
| May 21, 2025 | Owen Mahoney
Director
|
Grant | 2.6K | - |
| May 21, 2025 | Laurel J Richie
Director
|
Grant | 2.6K | - |
| May 21, 2025 | Richard S. Stoddart
Chairman of the Board
|
Grant | 2.6K | - |
| May 21, 2025 | West Mary Elizabeth Stone
Director
|
Grant | 2.6K | - |
Source: TwelveData, from SEC Form 4 filings
HAS stock forecast: questions people ask
Answered from the figures on this page, as of November 6, 2026.